Meridian's Fiscal Q1 Preliminary Results Fall Short of Expectations | GenomeWeb

NEW YORK (GenomeWeb News) - Meridian Bioscience today reported $44.8 million in preliminary revenue for its fiscal first quarter, marking a 1 percent decline from the year-ago period and falling short of consensus analyst estimates of $49 million.

The company attributed the disappointing results to several factors, including reduced hospital admissions, declining C. difficile incidence rates, shipment delays in its Life Science business, timing of the start of the influenza season, and food test ordering patterns.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.